Related references
Note: Only part of the references are listed.Induction of Regulatory T Cells and Correction of Cytokine Disbalance by Short-Chain Fatty Acids: Implications for Psoriasis Therapy
Agatha Schwarz et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
An Autocrine Circuit of IL-33 in Keratinocytes Is Involved in the Progression of Psoriasis
Fanfan Zeng et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
The Role of Helper T Cells in Psoriasis
Peng Hu et al.
FRONTIERS IN IMMUNOLOGY (2021)
Qinzhuliangxue mixture alleviates psoriasis-like skin lesions via inhibiting the IL6/STAT3 axis
Ke-Shen Qu et al.
JOURNAL OF ETHNOPHARMACOLOGY (2021)
Serum Expression of IL-33 and ST2 in Patients with Psoriasis Vulgaris
Yonghua Dong et al.
ARCHIVES OF IRANIAN MEDICINE (2021)
Taxifolin attenuates IMQ-induced murine psoriasis-like dermatitis by regulating T helper cell responses via Notch1 and JAK2/STAT3 signal pathways
Xiaohong Yuan et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
IL-33/13 Axis and IL-4/31 Axis Play Distinct Roles in Inflammatory Process and Itch in Psoriasis and Atopic Dermatitis
Khaldon Bodoor et al.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2020)
TLR2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation through Decrease in Regulatory T Cells and Impaired IL-10 Production
Momoko Nakao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes
Shuna Sun et al.
CELL DEATH & DISEASE (2019)
Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors
Camila Cataldi et al.
INFLAMMATION RESEARCH (2019)
IL-33 contributes to disease severity in Psoriasis-like models of mouse
Yaju Duan et al.
CYTOKINE (2019)
Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis
Teruo Shimizu et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2019)
Possible Roles of IL-33 in the Innate-Adaptive Immune Crosstalk of Psoriasis Pathogenesis
Serafinella Patrizia Cannavo et al.
MEDIATORS OF INFLAMMATION (2019)
Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family
Corinne Cayrol et al.
IMMUNOLOGICAL REVIEWS (2018)
Psoriasis: A STAT3-Centric View
Enzo Calautti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Serum IL-33 levels are increased in patients with psoriasis
A. Mitsui et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2016)
IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo
Mario Vaccaro et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2016)
Luteolin-7-glucoside inhibits IL-22/STAT3 pathway, reducing proliferation, acanthosis, and inflammation in keratinocytes and in mouse psoriatic model
R. Palombo et al.
CELL DEATH & DISEASE (2016)
Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis
Andrea Primiani Moy et al.
JAMA DERMATOLOGY (2015)
STAT1 expression and activation is increased in lesional psoriatic skin
A. Hald et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity
Rosa M. Andres et al.
EXPERIMENTAL DERMATOLOGY (2013)
Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor
M. -M. Suttle et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2012)
IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation
Anna Balato et al.
EXPERIMENTAL DERMATOLOGY (2012)
IL-33 induces skin inflammation with mast cell and neutrophil activation
Axel J. Hueber et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Stat3 as a Therapeutic Target for the Treatment of Psoriasis: A Clinical Feasibility Study with STA-21, a Stat3 Inhibitor
Ken Miyoshi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
A comparison of Ki-67 antigen presentation in acute generalized exanthematous pustulosis and pustular psoriasis
Shyue-Luen Chang et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2010)
IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin
Theoharis C. Theoharides et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Share Paper
